This article was originally published on 28 August 2015 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
Top-line results
The top four vaccine companies reported combined sales of approximately $5 billion in Q2 2015 and $9.3 billion for H1 2015, a broadly stable performance compared to the prior year period. The figures reflect a market still consolidating following the major M&A activity of 2014, including the GSK-Novartis vaccine asset exchange.
Combined H1 2015 vaccine revenues for the top four major vaccine players
GSK: Mosquirix positive CHMP opinion
The standout R&D milestone of the quarter was the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for GSK's malaria vaccine RTS,S/AS01 (MosquirixTM). This was a historic moment: the first malaria vaccine to receive a positive regulatory opinion. The recommendation was for use in children aged 6 weeks to 17 months in regions where malaria is moderate to high transmission. Whilst not a high-efficacy vaccine by conventional standards - demonstrating approximately 30-50% efficacy in different age groups - the sheer scale of malaria burden means even partial protection represents a significant public health contribution.
Sanofi: dengue vaccine regulatory submissions
Sanofi Pasteur progressed its CYD-TDV dengue vaccine (Dengvaxia®) through regulatory submissions in multiple endemic countries in 2015. Phase III efficacy data from large studies in Asia and Latin America had demonstrated overall vaccine efficacy of approximately 60.8% and had shown particular protection against hospitalisation and severe dengue. Questions remained around efficacy in seronegative individuals - an issue that would later become central to ongoing regulatory and public health discussions.
Pfizer: Trumenba ACIP category B recommendation
Pfizer's meningococcal serogroup B vaccine Trumenba® (bivalent rLP2086) received an ACIP Category B recommendation in the US, meaning vaccination is recommended for individuals at increased risk and can be considered for those aged 16-23 years. This positioned the vaccine alongside Novartis' Bexsero® in the US adolescent market, providing payers and clinicians with two MenB options.
Merck: Gardasil-9 uptake
Merck's nine-valent HPV vaccine Gardasil-9, which had received FDA approval in December 2014, was gaining traction in the US market. The expanded coverage over seven oncogenic HPV types compared to the original Gardasil (four types) was expected to further reduce the burden of HPV-related cancers.